Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma

NCT02875132 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT02875132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02875132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2017
Completion date
February 28, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acral lentiginous melanoma